Xenon Pharmaceuticals Inc.

December 9, 2021
img: Featured

In December 2019, Neurocrine Biosciences entered into a license and collaboration agreement with Xenon Pharmaceuticals to identify, research, and develop sodium channel inhibitors, including clinical candidate NBI-921352 and three preclinical candidates, which it will have the exclusive right to further develop and commercialize. NBI-921352 is a selective sodium channel inhibitor (Nav1.6) being developed to treat pediatric patients with SCN8A-DEE and other potential indications, including focal onset seizures.